Recombinant human activated protein C in the treatment of acute respiratory distress syndrome: A randomized clinical trial

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Cornet, Alexander D ^a,b   Groeneveld, A B Johan ^a,b,c   Hofstra, Jorrit J ^d   Vlaar, Alexander P ^d   Tuinman, Pieter R ^d   Van Lingen, Arthur ^a   Levi, Marcel ^d   Girbes, Armand R J ^a,b   Schultz, Marcus J ^d   Beishuizen, Albertus ^a,b,e  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; TRANSFERRIN GA 67; PROTEIN C; RECOMBINANT PROTEIN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INTENSIVE CARE UNIT; LUNG INJURY; LUNG INJURY SCORE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NON INVASIVE MEASUREMENT; OUTCOME ASSESSMENT; PERMEABILITY; PNEUMOTHORAX; PROSPECTIVE STUDY; PULMONARY LEAK INDEX; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SINGLE BLIND PROCEDURE; TREATMENT DURATION; AGED; MIDDLE AGED; RESPIRATORY DISTRESS SYNDROME, ADULT;

AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN C; RECOMBINANT PROTEINS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84898476969     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090983     Document Type: Article

References (40)

1. Wind J, Versteegt J, Twisk J, van Bindels AJ, Spijkstra JJ, et al. (2007) Epidemiology of acute lung injury and acute respiratory distress syndrome in The Netherlands: a survey. Respir Med 101:2091-2098 (Pubitemid 47324255)
2. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. (2012) Acute respiratory distress syndrome: the Berlin definition. JAMA 307:2526-2533
3. Cepkova M, Matthay MA (2006) Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med 21:119-143
4. Raijmakers PG, Groeneveld AB, Schneider AJ, Teule GJ, van Lingen A, et al. (1993) Transvascular transport of 67Ga in the lungs after cardiopulmonary bypass surgery. Chest 104:1825-1832 (Pubitemid 23360121)
5. 67Gallium pulmonary leak index in assessing the severity and course of the adult respiratory distress syndrome. Crit Care Med 24:1467-1472
6. Verheij J, Raijmakers PG, van Lingen A, Groeneveld AB (2005) Simple versus complex radionuclide methods of assessing capillary protein permeability for diagnosing acute respiratory distress syndrome. J Crit Care 20:162-171 (Pubitemid 41219637)
7. Groeneveld AB, Verheij J (2006) Extravascular lung water to blood volume ratios as measures of permeability in sepsis-induced in ALI/ARDS. Intensive Care Med 32:1315-1321 (Pubitemid 44267918)
8. Groeneveld AB, Kindt I, Raijmakers PG, Hack CE, Thijs LG (1994) Systemic coagulation and fibrinolysis in patients with or at risk for the adult respiratory distress syndrome. Thromb Haemost 78:1444-1449
9. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS (2006) Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia - a review. Crit Care Med 34:871-877
10. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, et al. (2007) Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 35:1821-1828 (Pubitemid 47220354)
11. Cornet AD, van Nieuw Amerongen GP, Beishuizen A, Schultz MJ, Girbes AR, et al. (2009) Activated protein C in the treatment of acute lung injury and acute respiratory distress syndrome. Exp Opin Drug Discovery 4:219-227
12. Nick JA, Coldren CD, Geraci MW, Poch KR, Fouty BW, et al. (2004) Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 104:3878-3885 (Pubitemid 39620133)
13. Van der Poll T, Levi M, Nick JA, Abraham E (2005) Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 171:1125-1128 (Pubitemid 40663724)
14. Finigan JH, Boueiz A, Wilkinson E, Damico R, Skirball J, et al. (2009) Activated protein C protects against ventilator-induced pulmonary capillary leak. Am J Physiol Lung Cell Mol Physiol 296:L1002-1011
15. Bir N, Lafarque M, Howard M, Goolaerts A, Roux J, et al. (2011) Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosa-induced lung injury in mice. Am J Respir Cell Mol Biol 45:632-641
16. Van der Heijden M, van Nieuw Amerongen GP, Koolwijk P, van Hinsbergh VW, Groeneveld AB (2008) Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. Thorax 63:903-909
17. Bae J-S, Rezaie AR (2010) Thrombin upregulates the angiopoietin-Tie2 axis: endothelial protein C receptor occupancy prevents the thrombin mobilization of angiopoietin 2 and P-selectin from Weibel-Palade bodies. J Thromb Haemost 8:1107-1115
18. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709 (Pubitemid 32204987)
19. Vincent J-L, Angus DC, Artigas A, Kalil A, Basson BR, et al. (2003) Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 31:834-840 (Pubitemid 36379592)
20. Vincent JL, Bernard GR, Beale R, Doig C, Putensen, et al. (2005) Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33:2266-2277 (Pubitemid 41437481)
21. Ely W, Laterre P-F, Angus DC, Helterbrand JD, Levy H, et al. (2003) Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 31:12-19 (Pubitemid 36151143)
22. Laterre PF, Garber G, Levy H, Wunderink R, Kinasewitz GT, et al. (2005) Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 33:952-961 (Pubitemid 40638163)
23. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, et al. (2005) Drotrecogin alfa (activated) for adults with severe sepsis and low risk of death. N Engl J Med 353:1332-1341 (Pubitemid 41362701)
24. Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, et al. (2007) Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 369:836-843 (Pubitemid 46365900)
25. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, et al. (2012) Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366:2055-2064
26. Kalil AC, LaRosa SP (2012) Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression. Lancet Infect Dis 12:678-686
27. Cornet AD, Hofstra JJ, Vlaar AP, Tuinman PR, Levi M, et al. (2013) Activated protein C attenuates pulmonary coagulopathy in patients with acute respiratory distress syndrome. J Thromb Haemost 11:894-901
28. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, et al. (2003) SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31:1250-1256 (Pubitemid 36444440)
29. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, et al. (1994) The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149:818-824 (Pubitemid 24082248)
30. Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHEII: a severity of disease classification system. Crit Care Med 13:818-829 (Pubitemid 15250137)
31. Raijmakers PG, Groeneveld AB, Teule GJ, Thijs LG (1996) Diagnostic value of the gallium-67 pulmonary leak index in pulmonary edema. J Nucl Med 37:1316-1322 (Pubitemid 26330663)
32. Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957-2963 (Pubitemid 24000804)
33. Vincent JL, Moreno R, Takala J, Willatts S, de Mendonca MA, et al. (1996) The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. Intensive Care Med 22:707-710 (Pubitemid 26254283)
34. Murray JF, Matthay MA, Luce JM, Flick MR (1988) An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 138:720-723
35. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, et al. (2008) Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 178:18-23
36. Choi G, Hofstra JJ, Roelofs JJ, Florquin S, Bresser P, et al. (2007) Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med 35:1362-1368 (Pubitemid 46642667)
37. Hofstra JJ, Vlaar AP, Cornet AD, Dixon B, Roelofs JJ, et al. (2010) Nebulized anticoagulants limit pulmonary coagulopathy, but not inflammation in a model of experimental lung injury. J Aerosol Pulm Drug Deliv 23:105-111
38. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, et al. (2006) Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 354:2564-2575 (Pubitemid 43882352)
39. Taccone P, Pesenti A, Latini R, Polli F, Vagginelli F, et al. (2009) Prone positioning in patients with moderate and severe acute respiratory distress syndrome: a randomized trial. JAMA 302:1977-1984
40. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, et al. (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Intensive Care Med 39:165-228